OBJECTIVE: To determine the long-term outcome of patients with monoclonal gammopathy of undetermined significance (MGUS). PATIENTS AND METHODS: We reviewed the medical records of 241 patients with MGUS who were examined at the Mayo Clinic in Rochester, Minn, between January 1, 1956, and December 31, 1970. RESULTS: Follow-up was 3579 person-years (median, 13.7 years; range, 0-39 years). Only 14 patients (6%) were alive and had no substantial increase of M protein at last follow-up; 138 patients (57%) died without evidence of multiple myeloma or a related disorder; a malignant lymphoplasma cell proliferative disorder developed in 64 patients (27%). The interval from diagnosis of MGUS to diagnosis of multiple myeloma or related disorder ranged from 1 to 32 years (median, 10.4 years). CONCLUSIONS: The median survival rate of study patients with MGUS was only slightly shorter than that of a comparable US population. Risk of progression of MGUS to lymphoplasma cell malignancy is indefinite and persists even after more than 30 years of follow-up, with no reliable predictors of malignant evolution.
OBJECTIVE: To determine the long-term outcome of patients with monoclonal gammopathy of undetermined significance (MGUS). PATIENTS AND METHODS: We reviewed the medical records of 241 patients with MGUS who were examined at the Mayo Clinic in Rochester, Minn, between January 1, 1956, and December 31, 1970. RESULTS: Follow-up was 3579 person-years (median, 13.7 years; range, 0-39 years). Only 14 patients (6%) were alive and had no substantial increase of M protein at last follow-up; 138 patients (57%) died without evidence of multiple myeloma or a related disorder; a malignant lymphoplasma cell proliferative disorder developed in 64 patients (27%). The interval from diagnosis of MGUS to diagnosis of multiple myeloma or related disorder ranged from 1 to 32 years (median, 10.4 years). CONCLUSIONS: The median survival rate of study patients with MGUS was only slightly shorter than that of a comparable US population. Risk of progression of MGUS to lymphoplasma cell malignancy is indefinite and persists even after more than 30 years of follow-up, with no reliable predictors of malignant evolution.
Authors: Rishi K Wadhera; Robert A Kyle; Dirk R Larson; Angela Dispenzieri; Shaji Kumar; Hillard M Lazarus; S Vincent Rajkumar Journal: Blood Date: 2011-07-15 Impact factor: 22.113
Authors: Robert A Kyle; Terry M Therneau; Angela Dispenzieri; Shaji Kumar; Joanne T Benson; Dirk R Larson; L Joseph Melton; S Vincent Rajkumar Journal: Clin Lymphoma Myeloma Leuk Date: 2013-03-13
Authors: Sigurdur Y Kristinsson; Magnus Björkholm; Therese M-L Andersson; Sandra Eloranta; Paul W Dickman; Lynn R Goldin; Cecilie Blimark; Ulf-Henrik Mellqvist; Anders Wahlin; Ingemar Turesson; Ola Landgren Journal: Haematologica Date: 2009-07-16 Impact factor: 9.941
Authors: Brenda M Birmann; Marian L Neuhouser; Bernard Rosner; Demetrius Albanes; Julie E Buring; Graham G Giles; Qing Lan; I-Min Lee; Mark P Purdue; Nathaniel Rothman; Gianluca Severi; Jian-Min Yuan; Kenneth C Anderson; Michael Pollak; Nader Rifai; Patricia Hartge; Ola Landgren; Lawrence Lessin; Jarmo Virtamo; Robert B Wallace; JoAnn E Manson; Graham A Colditz Journal: Blood Date: 2012-10-16 Impact factor: 22.113